Bone Biologics Corp. operates in the biotechnology sector, focusing on products that enhance bone growth and regeneration. The company's primary aim is to develop and commercialize NELL-1, a proprietary protein that has shown potential in accelerating bone repair and treating spinal fusion. Bone Biologics targets medical conditions requiring bone regeneration, such as spinal disorders, osteoporosis, and other orthopedic and neurosurgical needs. The innovations by Bone Biologics are poised to influence both the healthcare and biotechnology industries by offering alternatives to existing bone graft solutions. As Bone Biologics continues its research and development efforts, it aims to address critical gaps in surgical outcomes with products that enhance patient recovery.
Website2 Burlington Woods Drive
Burlington, MA, 01803
United States
Addition of three sites strengthens expectation to complete enrollment by year-end 2026BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, the Company’s rhNELL-1-based bone graft product for spinal fusion. Th
BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Jeff Frelick, Chief Executive Officer of Bone Biologics will hold one-on-one meetings with investors
Bone Biologics has extended the validated shelf life of its rhNELL-1 protein to 32 months, giving the company greater manufacturing and supply-chain flexibility as it prepares for larger-scale clinical development and advances enrollment in its first-in-human NB1 study. Key Investor TakeawaysBone Biologics (NASDAQ:BBLG) has achieved a 32-month validated shelf life for rhNELL-1, extending the 29-month milestone reported in May 2026.
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics
Investors talking about BBLGW also mention
| # | Name | Attention |
|---|---|---|
| 1 | SEI Select International Equity ETFSEIE | 0%0 |
| 2 | Chemung Financial CorporationCHMG | 0%0 |
| 3 | ClearBridge Large Cap Growth Select ETFLRGE | 0%0 |
| 4 | Commercial Vehicle Group IncCVGI | 0%0 |
| 5 | Aemetis Inc.AMTX | 0%-0.01 |
| 6 | Full House Resorts Inc.FLL | 0%0 |
| 7 | Katapult Holdings Inc.KPLT | 0%-0.01 |
| 8 | Morningstar Inc.MORN | 0%-0.02 |
| 9 | Ocugen Inc.OCGN | 0.02%-0.01 |
| 10 | GWII - Good Works II Acquisition Corp. | —— |
What share of all stock conversation is about BBLGW?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% 0 |
Of the messages about BBLGW that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 100% | ||
| Bearish | — | — | — | 0% |
Of the messages about BBLGW that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Analysts | — | — | — | 100% | ||
| Announcements | — | — | — | 0% | ||
| Controversies | — | — | — | 0% | ||
| Earnings | — | — | — | 0% | ||
| Macro | — | — | — | 0% | ||
| Technical Analysis | — | — | — | 0% |
Of the messages about BBLGW, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | — | 0% | ||
| Newcomers | — | — | — | 100% |